sitagliptin


Also found in: Medical, Wikipedia.

sit·ag·lip·tin

 (sĭt′ə-glĭp′tn)
n.
An oral hypoglycemic drug, C16H15F6N5O, used in its phosphate form to treat type 2 diabetes.

[sita-, of unknown origin + -gliptin, hypoglycemic drug suffix; see saxagliptin.]
Translations

sitagliptin

n sitagliptina
References in periodicals archive ?
Request of Proposal for Supply of medicine Common Cold Tab (Antihistiminics + Paracetamol 500 mg without pseudoephedrine),Itraconazole 100mg Cap, Tab Sitagliptin 50 mg + Metformin 1000 mg, Atorvastatin 20 mg Tab, Asprin 75 mg Tab, Acarbose 25 mg Tab, Tab Sitagliptin 100 mg, Linagliptin 5mg Tab, Gabapentin 100 mg Cap, Pioglitazone Hcl 30 mg Tab
There are four drugs in this subclass: alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin (Onglyza), and sitagliptin (Januvia).
In the studies, both doses of ertugliflozin tested (five mg and 15 mg daily) achieved statistically significant decrease in A1C, a measure of average blood glucose over a two- to three-month timeframe, when added to metformin or in initial co-administration with sitagliptin.
In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically significant reductions in A1C, a measure of average blood glucose over a two- to three-month timeframe, when added to metformin or in initial co-administration with sitagliptin.
One common API, sitagliptin phosphate--hereby referred to as sitagliptin--will be used as an example to illustrate this methodology.
NEITHER SAXAGLIPTIN NOR sitagliptin, the two oral DPP-4 inhibitors most commonly used as antihyperglycemic medications, raised the risk of hospitalization for heart failure in a large population-based cohort study that analyzed data from a Food and Drug Administration surveillance program.
At the recent 51st European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, new Phase 3 data on Merck's investigational once-weekly oral DPP-4 inhibitor, omarigliptin, and additional findings from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of Januvia were presented.
Findings of this study showed that Sitagliptin did not increase the risk of major adverse cardiovascular events in the Primary Composite Endpoint, or Hospitalization for Heart Failure compared with Placebo.
Dubai: A well-known diabetes medication, Sitagliptin, that is widely used around the world and in the UAE, has been found safe for heart patients.
Background: Sitagliptin, an oral and selective dipeptidyl peptidase-4 inhibitor, represents a novel therapeutic approach for the treatment of type 2 diabetes mellitus.
Sitagliptin is a selective DPP-4 inhibitor and it was approved for the treatment of type 2 diabetes mellitus (T2DM) at the end of 2009 in Japan.